29 completed, 9 withdrawn, 6 unknown, 5 terminated. 22 Phase 4, 9 Phase 2, 9 Phase 3, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Completed 8, Withdrawn 7, Terminated 5, Unknown 2 |
| Phase 2 | 9 | Completed 9 |
| Phase 3 | 9 | Completed 7, Withdrawn 2 |
| Phase 1 | 3 | Completed 3 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Unknown 1 |
Follow elbasvir-grazoprevir drug combination: new trials by email Literature Review of elbasvir-grazoprevir drug combination trials Research Report on elbasvir-grazoprevir drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] - Hepatitis C Virus Infection, Response to Therapy of | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2019-12-01 | 2020-04-20 | |
| Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] - Hepatitis C, Hemodialysis | Phase 4 | Completed | University of Pennsylvania | 6 | 2019-09-22 | 2021-12-15 |
| Zepatier in Patients with Substance Use Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] - Hepatitis C, Hiv | Completed | University of Illinois at Chicago | 25 | 2019-09-20 | 2025-01-28 | |
| HepATocellular Cancer Hcv Therapy Study Elbasvir / Grazoprevir Oral Tablet - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Withdrawn | Bayside Health | 2019-09-01 | 2020-09-14 | |
| ATTIC - Access To Treat in the Community ZEPATIER 50Mg-100Mg Tablet - Hepatitis C, Chronic | Phase 4 | Terminated | King's College Hospital NHS Trust | 13 | 2019-03-23 | 2023-05-06 |
| Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation grazoprevir 100 mg/ elbasvir 50 mg, Zepatier® - Chronic Hepatitis c, Liver Transplant Infection | Phase 4 | Terminated | Taichung Veterans General Hospital | 14 | 2019-02-14 | 2021-03-16 |
| A Prospective Cohort Study to Improve HCV Care in Dialysis Patients Zepatier - Hepatitis C | Phase 4 | Withdrawn | Albert Einstein Healthcare Network | 2019-01-01 | 2020-02-26 | |
| Transplanting Hepatitis C Lungs Into Negative Lung Recipients Zepatier, Epclusa - Lung Diseases | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 10 | 2018-12-12 | 2023-04-14 |
| Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI - Cardiovascular Diseases, Hepatitis C | Phase 4 | Completed | University of Maryland, Baltimore | 87 | 2018-11-18 | 2023-05-22 |
| Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan elbasvir/grazoprevir - Drug Interaction Potentiation | Completed | National Cheng-Kung University Hospital | 400 | 2018-10-22 | 2019-03-13 | |
| Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant Zepatier, Zepatier plus Sofosbuvir - Renal Failure Chronic, Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2018-10-01 | 2018-12-20 | |
| Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier] - Chronic HCV Hepatitis | Phase 3 | Completed | Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | 75 | 2018-09-19 | 2023-02-22 |
| Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin - Cardiac Transplant Disorder, Hepatitis C | Phase 4 | Withdrawn | Raymond T. Chung, MD | 2018-08-01 | 2018-12-20 | |
| A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk Elbasvir/grazoprevir - Hepatitis C | Phase 4 | Withdrawn | University of California, Los Angeles | 2018-08-01 | 2018-08-07 | |
| Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 Elbasvir, Grazoprevir 50-100Mg Oral Tablet - Hepatitis C, Chronic | Phase 3 | Completed | King Fahad Medical City | 30 | 2018-07-01 | 2020-11-20 |
| EBR/GZR for HCV-1b Patients Receiving Hemodialysis EBR/GZR - Hepatitis C | Phase 4 | Completed | National Taiwan University Hospital | 40 | 2018-06-05 | 2020-03-11 |
| Hepatitis C (HCV) Cure and Kidney Health Elbasvir / Grazoprevir Oral Tablet [Zepatier] - Hepatitis C | Unknown | San Francisco Veterans Affairs Medical Center | 50 | 2018-03-27 | 2018-04-18 | |
| The Dublin Zepatier Study Zepatier - Hepatitis C | Phase 4 | Terminated | Mater Misericordiae University Hospital | 3 | 2018-03-15 | 2019-12-10 |
| Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy Elbasvir/Grazoprevir - Hepatitis C, Cryoglobulinaemic Glomerulonephritis | Unknown | University of Florence | 45 | 2018-03-01 | 2018-02-14 | |
| Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) MK-5172A - Hepatitis C | Phase 4 | Withdrawn | Merck Sharp & Dohme LLC | 2018-02-12 | 2017-11-09 |
Showing 20 of 49. Sign in to see all of them.
Hepatitis C (38) · Hepatitis C, Chronic (6) · Substance-Related Disorders (4) · Acquired Immunodeficiency Syndrome (3) · Kidney Failure, Chronic (3) · Renal Insufficiency, Chronic (3) · Carcinoma, Hepatocellular (2) · Renal Insufficiency (2) · Cardiovascular Diseases (1) · Cross Infection (1) · HIV Infections (1) · Heart Failure (1) · Homosexuality (1) · Inflammation (1) · Insulin Resistance (1)
Merck Sharp & Dohme LLC (7) · University of Pennsylvania (4) · University of Maryland, Baltimore (3) · Massachusetts General Hospital (2) · National Taiwan University Hospital (2) · ANRS, Emerging Infectious Diseases (1) · Albert Einstein Healthcare Network (1) · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo (1) · Bayside Health (1) · Dallas VA Medical Center (1) · Fundacion SEIMC-GESIDA (1) · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba (1) · Johns Hopkins University (1) · Kaohsiung Medical University Chung-Ho Memorial Hospital (1) · King Fahad Medical City (1)
United States (19) · Taiwan (5) · France (3) · United Kingdom (2) · Australia (1) · Egypt (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1) · Norway (1) · Poland (1) · Saudi Arabia (1) · Spain (1) · Sweden (1)
Peter Reese, MD, MSCE (3) · Raymond Chung, MD (2) · Ahmed O Kaseb, MD (1) · Atif Zaman, MD (1) · Chen-Hua Liu, MD, PhD (1) · David R Nelson, MD (1) · Dominique L Braun, MD (1) · Eyob Feyssa, MD (1) · Faisal Abaalkhail, Md (1) · Gaurav Gupta, MD (1) · Goki Suda, Dr (1) · Greg Dore, MBBS (1)
PMID 28193518, PMID 29461687, PMID 27720838, PMID 27770561, PMID 16183464, PMID 20425880, PMID 23616960, PMID 23884067, PMID 23884071, PMID 25909356, PMID 26005037, PMID 28256747, PMID 29077864, PMID 29404492, PMID 29507971, PMID 29761174, PMID 30083748, PMID 30107485, PMID 30107494, PMID 30704882, PMID 30957170, PMID 31399460, PMID 31533734, PMID 31594667, PMID 31652392, PMID 31790766, PMID 32270056, PMID 32761122, PMID 33319038, PMID 33823783, PMID 34255381, PMID 34902265, PMID 35142658, PMID 35182741, PMID 35404384, PMID 35582875, PMID 35657133, PMID 35920743, PMID 36790337
2014 (3), 2015 (2), 2017 (2)